Neuromuscular

The phase 3 EMNERGIZE study evaluates whether the complement C2 inhibitor empasiprubart can improve disability and functional outcomes in adults with chronic inflammatory demyelinating polyneuropathy.

A preclinical study found that SP16, an LRP1 agonist, reduced mechanical hypersensitivity and cold hyperalgesia in paclitaxel-treated mice in an LRP1-dependent manner, implicating Schwann cell LRP1 as a potential therapeutic target in CIPPN.

A randomized, placebo-controlled study will assess whether weekly subcutaneous imeroprubart can reduce relapse risk in patients with chronic inflammatory demyelinating polyneuropathy despite standard-of-care treatment.

New phase 2 data showed that riliprubart was associated with sustained improvements in patient-reported outcomes at 76 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

The MAGNAZ trial, the first study evaluating zanubrutinib added to rituximab in anti-MAG polyneuropathy, reported baseline characteristics of 32 enrolled patients at PNS 2026, with efficacy results to follow.

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, discussed the current landscape of biomarkers in peripheral nerve disorders and the evolving role of neurofilament light chain in clinical care and research. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A real-world comparative study found efgartigimod produced similar GBS disability score improvement to plasma exchange at 4 weeks, with significantly greater MRC sum score recovery at weeks 8 and 12, and a comparable safety profile.

Analysis of 1420 patients from the International GBS Outcome Study found no significant difference in GBS disability scores between IVIg and plasma exchange at 4 or 26 weeks after adjusting for key clinical covariates.

An exploratory analysis of the phase 3 ADHERE trial found serum NfL levels correlated with CIDP disease activity and declined with efgartigimod treatment in patients with elevated baseline levels.

The CAPTIVATE trial evaluates claseprubart, an active C1s inhibitor, across a broad CIDP population including SOC responders, refractory patients, and treatment-naive adults, with time to relapse as the primary endpoint in the double-blind phase.

Despite missing its primary end point, the SYNAPSE-CMT trial showed improvements in muscle strength and motor function with ignaseclant treatment in patients with Charcot-Marie-Tooth disease.

A phase 4 trial underway in the U.S. is examining whether patients with CIDP on stable IVIg can transition to efgartigimod PH20 SC within one week of their last infusion, without requiring documented disease worsening first.

Sanofi stops the phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy because of insufficient likelihood of efficacy, with no safety signals reported.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Jinsy A. Andrews, MD, Director of the ALS Clinic and Director of Clinical Trials at NYU Langone Health, discussed the evolving ALS treatment landscape, including emerging gene-targeted therapies, and the next generation of disease biomarkers.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending May 30, 2026. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

New exon‑51 skipping therapy boosts dystrophin and patient strength, with upcoming trial readouts aiming to support accelerated FDA approval.

Here's some of what is coming soon to NeurologyLive® this week.

Karen Lynch, MD, MRCPI, senior global medical director at Sanofi, discussed ongoing unmet needs in CIDP, diagnostic challenges, and emerging research efforts evaluating complement inhibition and biomarker-driven care approaches.

Wearable accelerometer metric 6M95C tracks Duchenne progression beyond walking loss, delivering effort‑independent, real‑world outcomes to strengthen late‑stage clinical trials.

New phase 4 head-to-head data suggest Dysport may provide longer-lasting symptom control than Botox in adults with upper limb spasticity while maintaining comparable safety.